SummaryRMgm-308
|
Successful modification | The parasite was generated by the genetic modification | ||||||||||||||||
The mutant contains the following genetic modification(s) | Gene disruption | ||||||||||||||||
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 19779564 | ||||||||||||||||
MR4 number | |||||||||||||||||
top of page | |||||||||||||||||
Parent parasite used to introduce the genetic modification | |||||||||||||||||
Rodent Malaria Parasite | P. berghei | ||||||||||||||||
Parent strain/line | P. berghei ANKA | ||||||||||||||||
Name parent line/clone | P. berghei ANKA 2.34 | ||||||||||||||||
Other information parent line | P. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943). | ||||||||||||||||
top of page | |||||||||||||||||
The mutant parasite was generated by | |||||||||||||||||
Name PI/Researcher | R.W. Moon; D.A. Baker; O. Billker | ||||||||||||||||
Name Group/Department | Department of Cell and Molecular Biology | ||||||||||||||||
Name Institute | Imperial College London | ||||||||||||||||
City | London | ||||||||||||||||
Country | UK | ||||||||||||||||
top of page | |||||||||||||||||
Name of the mutant parasite | |||||||||||||||||
RMgm number | RMgm-308 | ||||||||||||||||
Principal name | pdeδ mutant | ||||||||||||||||
Alternative name | |||||||||||||||||
Standardized name | |||||||||||||||||
Is the mutant parasite cloned after genetic modification | Yes | ||||||||||||||||
top of page | |||||||||||||||||
Phenotype | |||||||||||||||||
Asexual blood stage | Not different from wild type | ||||||||||||||||
Gametocyte/Gamete | Not different from wild type | ||||||||||||||||
Fertilization and ookinete | Gametocyte production and fertilisation were not different from wild type. During the first 12h of in vitro culture, mutant zygotes differentiated into morphologically advanced ookinetes (stage IV-VI) in similar numbers as wild type. In cultures of wild ookinetes, mature ookinete forms continued to accumulate in in vitro culture, reaching 60% of all macrogamete-derived parasites by 24h, the remainder presumably being unfertilised macrogametes. In contrast, all the morphologically mature ookinetes in the early cultures (12h) of the mutant were replaced successively by stumpy and round forms and at 24h, hardly any typically shaped ookinetes were present. Motility of ookinetes was affected (see 'Additional information'). The mutant ookinetes had a greatly reduced capacity to develop into oocysts; oocyst numbers on the mosquito midgut epithelium were reduced by >94%. | ||||||||||||||||
Oocyst | The mutant ookinetes had a greatly reduced capacity to develop into oocysts; oocyst numbers on the mosquito midgut epithelium were reduced by >94%. | ||||||||||||||||
Sporozoite | Not tested | ||||||||||||||||
Liver stage | Not tested | ||||||||||||||||
Additional remarks phenotype | Mutant/mutation
Phenotype Aberrant differentiation of mutant ookinetes was not accompanied by parasite death, as judged by exclusion of the membrane impermeable SYTOX® green nucleic acid stain. In addition, injection of mutant ookinetes in the hemocoel, the ookinetes were able to produce oocysts and produced infective salivary gland sporozoites comparable to wild type ookinetes. Ultrastructural analyses of mutant ookinetes indicated the presence of a 'discontinuous' inner membrane complex (IMC) with gaps that varied in size In the paper evidence is presented that in ookinetes GCß is the main source for cGMP and that a cyclic GMP signalling module exists that regulates gliding motility of ookinetes. This evidence is partly based on the analysis of the mutant described here lacking expression PDEδ and a mutant lacking expression of both GCβ and PDEδ (RMgm-309). These analyses indicate that PDEδ is the relevant cGMP degrading enzyme. Signalling via a cGMP-dependent protein kinase (PKG; PF14_0346; PB000726.02.0) may regulate ookinete differentiation and motility. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1333700 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1470500 | ||||||||||||||||||||||||
Gene product | phosphodiesterase delta, putative | ||||||||||||||||||||||||
Gene product: Alternative name | PDEδ, phosphodiesterase delta | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | KpnI, BamHI | ||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |